Skip to main content
Top

Open Access 12-03-2025 | Breast Cancer | Research

Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada

Authors: Robert B. Basmadjian, Yuan Xu, May Lynn Quan, Sasha Lupichuk, Winson Y. Cheung, Darren R. Brenner

Published in: Breast Cancer Research and Treatment

Login to get access

Abstract

Introduction

Outcome prediction research in early-onset breast cancer (EoBC) is limited. This study evaluated the predictive performance of NHS PREDICT v2.1 and developed two prediction models for 5-year and 10-year all-cause mortality in a cohort of EoBC patients in Alberta, Canada.

Methods

Adults < 40 years diagnosed with invasive breast cancer in Alberta, Canada from 2004 to 2020 were included. Patient data were entered into PREDICT v2.1 and mortality estimates at 5 and 10 years were extracted. Two prediction models were developed for all-cause mortality: multivariable Cox regression with LASSO penalization (LASSO Cox) and random survival forests (RSF). Internal validation of the developed models was performed using nested tenfold cross-validation repeated 200 times. Model performance was assessed using receiver operator characteristic and calibration curves for mortality at 5 and 10 years.

Results

In total, 1827 patients with EoBC were eligible for inclusion. At 5 years, PREDICT had an area under the curve of 0.78 (95%CI 0.74–0.82) and overestimated mortality by 2.4% (95%CI 0.70–4.33) in the overall cohort. No differences in observed and predicted mortality by PREDICT were observed at 10 years. The LASSO Cox model showed better discrimination at 5 and 10 years than the RSF model, but both had poor calibration and underestimated mortality.

Conclusion

PREDICT v2.1 tended to overestimate 5-year mortality in those with > 30% predicted risks and 10-year mortality in those with > 50% predicted risks for EoBC in Alberta, Canada. We did not identify additional models that would be clinically useful by applying machine learning. More follow-up data and emerging systemic treatment variables are required to study outcome prediction in modern cohorts.
Appendix
Available only for authorised users
Literature
9.
go back to reference Cambridge Breast Unit University of Cambridge Department of Oncology and the UK’s Eastern Cancer Information and Registration Centre (ECRIC): Predict Breast Cancer. Winton Centre for Risk & Evidence Communication. https://breast.predict.nhs.uk/. Accessed Jan 2023 Cambridge Breast Unit University of Cambridge Department of Oncology and the UK’s Eastern Cancer Information and Registration Centre (ECRIC): Predict Breast Cancer. Winton Centre for Risk & Evidence Communication. https://​breast.​predict.​nhs.​uk/​. Accessed Jan 2023
25.
go back to reference Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating—chapters 4 & 5. Springer, New YorkCrossRef Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating—chapters 4 & 5. Springer, New YorkCrossRef
26.
go back to reference Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating—chapters 15–17. Springer, New YorkCrossRef Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating—chapters 15–17. Springer, New YorkCrossRef
Metadata
Title
Evaluating PREDICT and developing outcome prediction models in early-onset breast cancer using data from Alberta, Canada
Authors
Robert B. Basmadjian
Yuan Xu
May Lynn Quan
Sasha Lupichuk
Winson Y. Cheung
Darren R. Brenner
Publication date
12-03-2025
Publisher
Springer US
Published in
Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-025-07654-1

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video